Two popular antipsychotic medications made by Johnson & Johnson -- Risperdal and risperidone -- have been recalled due to possible contamination with a chemical used to treat the wood pallets ...

A new drug has been approved for a rare population -- teens with schizophrenia. The illness is typically diagnosed first in young adulthood, usually the early 20s. But the ...

The U.S. Food and Drug Administration is currently reviewing recent studies of food coloring and its effect on children's behavior.   In a preliminary report, ...

The maker of Citalopram and Finasteride announced a voluntary recall of the two drugs Saturday due to mislabeling and possible ingestion of the wrong drug by patients. Greenstone LLC, a subsidiary of drug giant Pfizer, announced that it is voluntarily conducting a recall, ...

Viibryd (vilazodone hydrochloride) was approved by the U.S. Food and Drug Administration Monday to treat major depression -- also known as clinical depression -- in adults. Viibryd is a one-of-a-kind ...

The U.S. Food and Drug Administration has approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia. "Schizophrenia can be a devastating illness requiring ...

On Thursday, the U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) -- an atypical antipsychotic medication -- for the treatment of adults with schizophrenia. Schizophrenia is characterized ...

The U.S. Food and Drug Administration (FDA) has given the green light to the nonstimulant medication Kapvay (clonidine hydrochloride) as the first drug used to treat attention deficit hyperactivity disorder (ADHD) that can be used as an add-on therapy to stimulant medication. Kapvay ...

A new side effect associated with the psychiatric medication Lamictal has been discovered. On August 12th the U.S. Food and Drug Administration (FDA) issued a new warning that Lamictal (lamotrigine) has a very low risk of causing a condition known as aseptic meningitis. “Aseptic meningitis is ...

After much review and public controversy, the FDA met this week and determined that flibanserin, a new medication that was hoped to be an effective treatment for female sexual arousal disorder, did not significantly improve symptoms of the disorder, and ...